Supporting these findings, in vivo administration of a selective inhibitor of IRAK4, BMS-986126, prevented the development of GN, plasma anti-dsDNA autoantibodies and reduced IFNa+pDCs in both NZB/W and MRLlpr mice, and splenic IL-6+CD11b+ myeloid cells in latter (46). This evidence concerns the gene IRAK4 and ganglioneuroma.